$BIIB Recent Headlines AT&T, Yelp shares decline after

New Post Public Reply Private Reply Replies (0) Message Board

Nov 3, 2014 at 11:57 AM

$BIIB Recent Headlines

AT&T, Yelp shares decline after earnings 5:48 p.m. Oct. 22, 2014 - Sue Chang
U.S. stocks wither; S&P 500 ends 4-day win steak 4:39 p.m. Oct. 22, 2014 - Carla Mozee
Updates, advisories and surprises 4:31 p.m. Oct. 22, 2014 - MarketWatch
Biogen shares drop on Tecfidera patient death 11:48 a.m. Oct. 22, 2014 - Russ Britt
Icahn says buying Apple is a ‘no-brainer’, and a first-ever for the VIX 11:37 a.m. Oct. 22, 2014 - Barbara Kollmeyer
Biogen Idec shares slump 7.6% 9:32 a.m. Oct. 22, 2014 - Sue Chang
Biogen shares turn lower; analyst says key MS drug sales missed expectations 8:37 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares turn lower, down 2.7% premarket after Q3 results 8:13 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen beats estimates on strong MS drug sales 7:49 a.m. Oct. 22, 2014 - MarketWatch.com
Biogen shares rally after beating profit expectations, raising outlook 7:15 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares gain 0.7% premarket after Q3 results 7:06 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen ups full-year adj. EPS outlook to $13.45-$13.55 vs. FactSet estimate $13.10 7:05 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 net EPS $3.62 vs. $2.05 a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 FactSet sales consensus $2.48 bln 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 sales $2.51 bln vs. $1.83 bln a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 adj. EPS $3.80 vs. FactSet consensus $3.45 7:02 a.m. Oct. 22, 2014 - Tomi Kilgore
Boeing, AT&T reports due Wednesday; Yahoo up late 6:48 p.m. Oct. 21, 2014 - Sue Chang
More than 1/3 of Dow stocks to report this week 5:30 a.m. Oct. 19, 2014 - Wallace Witkowski
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn

20 Stocks That Could Beat the Market in November 9:50 a.m. Today - TheStreet.com
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog 4:30 p.m. Oct. 31, 2014 - Zacks.com
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog 3:30 p.m. Oct. 31, 2014 - Zacks.com
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog 1:49 p.m. Oct. 31, 2014 - Zacks.com
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog 1:20 p.m. Oct. 31, 2014 - Zacks.com
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog 10:57 a.m. Oct. 31, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Biogen Idec (BIIB) 9:50 a.m. Oct. 31, 2014 - TheStreet.com
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape 9:46 a.m. Oct. 31, 2014 - Zacks.com
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape 9:11 a.m. Oct. 31, 2014 - Zacks.com
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX 6:00 a.m. Oct. 31, 2014 - TheStreet.com
Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14) 5:46 a.m. Oct. 31, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong 8:11 p.m. Oct. 30, 2014 - TheStreet.com
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog 2:50 p.m. Oct. 30, 2014 - Zacks.com
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape 9:25 a.m. Oct. 30, 2014 - Zacks.com
Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary 8:00 a.m. Oct. 30, 2014 - Zacks.com
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog 3:05 p.m. Oct. 29, 2014 - Zacks.com
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog 2:00 p.m. Oct. 29, 2014 - Zacks.com
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog 1:00 p.m. Oct. 29, 2014 - Zacks.com
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog 12:28 p.m. Oct. 29, 2014 - Zacks.com
One More Time: The Genzyme Contingent Value Right 10:15 a.m. Oct. 29, 2014 - Seeking Alpha

3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Today - BusinessWire - BZX
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review 4:10 p.m. Oct. 31, 2014 - Thomson Reuters ONE
Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review 4:05 p.m. Oct. 31, 2014 - BusinessWire - BZX
Quarterly Earnings Releases, Technical Updates, Software Launches, Welfare Initiatives, and New Health Plans - Research Reports on Biogen, Express Scripts, Covidien, Alexion and Aetna 8:45 a.m. Oct. 30, 2014 - PR Newswire - PRF
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin 8:40 a.m. Oct. 29, 2014 - PR Newswire - PRF
Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases 7:30 a.m. Oct. 23, 2014 - BusinessWire - BZX
Regulatory Approval, Customer Safety Alert, Patient Support Program Launch, Earnings Releases, and Rating - Research Reports on Medtronic, Covidien, Biogen Idec, Baxter and Express Scripts 8:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals 8:01 a.m. Oct. 15, 2014 - BusinessWire - BZX
Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire 8:30 a.m. Oct. 13, 2014 - PR Newswire - PRF
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe 3:01 p.m. Oct. 9, 2014 - Thomson Reuters ONE
CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 4:01 p.m. Oct. 8, 2014 - BusinessWire - BZX
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 5:34 p.m. Sept. 25, 2014 - BusinessWire - BZX
Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire 9:25 a.m. Sept. 23, 2014 - PR Newswire - PRF
Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index 8:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy 7:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec 2:01 a.m. Sept. 19, 2014 - Thomson Reuters ONE
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders 7:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp. 8:40 a.m. Sept. 15, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Brightstar Extends ONCE Contract for Spain Lottery Tech

Brightstar's Steady Hand in the Lottery Fray Now here's a story that's got a touch of nostalgia coupled with forward-thinking ambition. Brightstar Lottery PLC, the big kahuna if you're talking about lottery tech, just snagged a multi-year contract extension with Spain's ONCE— the folks known for funding social programs with their lotteries. It’s not just any little...

Equity Alerts: Unraveling the Latest M&A Surprises

Diving Into the M&A Controversy On the bustling streets of New York, beneath the towering Empire State Building, a plot unfolds that could shake the foundations of your investments—particularly if you're holding shares in Synaptics, Eagle Financial, Victory Capital, or Centerspace. Juan Monteverde and his legal firepower from Monteverde & Associates PC are launching a...

Bambu Lab Shakes Up 3D Printing with Massive Discounts

Price Cuts Bring 3D Printing Mainstream Here's the deal—3D printing used to be the domain of the tech-savvy elite, akin to those early computer geeks holed up in garages. But now? Bambu Lab is throwing open those doors with its Black Friday and Cyber Monday specials, slashing prices like a man on a mission. They're bringing an entire technological leap into our hands,...

Millrose Faces Class Action: Blame Game in Motion

Millrose Properties: A Realty Ruckus Unfolding Sometimes, in the world of stocks, it feels like you're two steps ahead of the scam or already knee-deep in trouble. Millrose Properties, Inc. struck a rather sour chord recently with an 8.53% stock drop, leaving investors feeling the burn. Here's the juice: a securities fraud class action is in motion, and if you're holding...

Paige Kaplan Randolph Spotlights on Hollywood Power List

From Law Books to Power Lists Cue the applause, folks! Paige Kaplan Randolph has just snagged a shiny badge of honor being named to The Hollywood Reporter's Power Reps: Creators List for 2026. This ain't some random nod; it's a recognition spotlighting legal stalwarts shaping the ever-morphing mosaic of entertainment. If you're wondering where the real power behind the...

Quantum Connections Elevates Griffeth to COO Role

James Griffeth Steps Up: A Strategic Shift Quantum Connections has handed James "Jamie" Griffeth the keys to the operational kingdom, elevating him to Chief Operating Officer. This isn't just any old promotion mind you—he'll also keep steering the ship as Director of the Dialogue Training Institute. It’s strategic moves like these that can make or break futures. The...

Vermilion Energy Sets Dates for Earnings and Calls

The Anticipation Around Vermilion's Upcoming Results There's a buzz in the air about Vermilion Energy Inc.'s upcoming Q3 2026 financial results. Slated to hit the wires November 4th, before the sun rises on Wall Street, folks in the trade have their eyes peeled to parse through any morsels of data. The question on everyone's mind? Whether they're making the right moves to...

Ransomware Hits The Money Store, Data at Risk

Ransomware in the Mortgage Sector Feels like data breaches are the new rainy day—unwelcome and unavoidable. This time, the storm hit MLD Mortgage Inc., otherwise known as The Money Store. You’d think that with a name like that, they'd keep a tight grip on their data. But nope, they've got a mess on their hands, and Edelson Lechtzin LLP is on the case, poking into this...

Asuri.ai Unveils Multi-Agent AI Platform for Business

Asuri.ai's Bold New Move into AI Workflows Picture the business world, bustling with nontechnical folks drowning in redundant tasks. Now toss a lifeline: Asuri.ai's fresh-off-the-presses multi-agent enterprise AI platform. This isn't just another tricked-out AI assistant; it's a serious game-changer on October 21, 2026. From Irvine, California, Asuri has kicked open a...

Factors Driving Up Car Window Tinting Costs Explained

Decoding the Dollars Behind Car Window Tinting When you think about car upgrades, window tinting might not scream excitement. But, my friends, it ain't all about the aesthetics. Dive into the nuts and bolts of cost with insights from Francis Alegre, a seasoned pro from StayShine Detailing in Voorhees, New Jersey, featured in HelloNation's rundown. The Glass Mass Factor...